Published online before print April 24, 2008

This Article Full Text (Reprint (PDF)) All Versions of this Article: jlb.0208090v1 84/1/302    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Glinka, Y. Articles by Prud'homme, G. J. Search for Related Content PubMed PubMed Citation Articles by Glinka, Y. Articles by Prud'homme, G. J.

© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0208090

Received for publication February 6, 2008.
Revised March 7, 2008.
Accepted for publication March 24, 2008.

Article

Neuropilin-1 is a receptor for transforming growth factor -1, activates its latent form, and promotes regulatory T cell activity

Department of Laboratory Medicine, St. Michael's Hospital and University of Toronto, Ontario, Canada

^@ To whom correspondence should be addressed. E-mail: glinkay{at}smh.toronto.on.ca.

Abstract

Neuropilin-1 (Nrp1) is a multifunctional protein, identified principally as a receptor for the class 3 semaphorins and members of the vascular endothelial growth factor (VEGF) family, but it is capable of other interactions. It is a marker of regulatory T cells (Tr), which often carry Nrp1 and latency-associated peptide (LAP)-TGF-1 (the latent form). The signaling TGF-1 receptors bind only active TGF-1, and we hypothesized that Nrp1 binds the latent form. Indeed, we found that Nrp1 is a high-affinity receptor for latent and active TGF-1. Free LAP, LAP-TGF-1, and active TGF-1 all competed with VEGF₁₆₅ for binding to Nrp1. LAP has a basic, arginine-rich C-terminal motif similar to VEGF and peptides that bind to the b1 domain of Nrp1. A C-terminal LAP peptide (QSSRHRR) bound to Nrp1 and inhibited the binding of VEGF and LAP-TGF-1. We also analyzed the effects of Nrp1/LAP-TGF-1 coexpression on T cell function. Compared with Nrp1^– cells, sorted Nrp1⁺ T cells had a much greater capacity to capture LAP-TGF-1. Sorted Nrp1^– T cells captured soluble Nrp1-Fc, and this increased their ability to capture LAP-TGF-1. Conventional CD4⁺CD25^–Nrp1^– T cells coated with Nrp1-Fc/LAP-TGF-1 acquired strong Tr activity. Moreover, LAP-TGF- was activated by Nrp1-Fc and also by a peptide of the b2 domain of Nrp1 (RKFK; similar to a thrombospondin-1 peptide). Breast cancer cells, which express Nrp1, also captured and activated LAP-TGF-1 in a Nrp1-dependent manner. Thus, Nrp1 is a receptor for TGF-1, activates its latent form, and is relevant to Tr activity and tumor biology.

Key Words: binding motif • VEGF • LAP-TGF-1 • signal transduction • CD4⁺CD25^– • T lymphocytes • suppressor cells

This article has been cited by other articles:

				L. Capparuccia and L. Tamagnone Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin J. Cell Sci., June 1, 2009; 122(11): 1723 - 1736. [Abstract] [Full Text] [PDF]

				A. W. Taylor Review of the activation of TGF-{beta} in immunity J. Leukoc. Biol., January 1, 2009; 85(1): 29 - 33. [Abstract] [Full Text] [PDF]